169 related articles for article (PubMed ID: 11973010)
21. Selective mediation of nerve injury-induced tactile hypersensitivity by neuropeptide Y.
Ossipov MH; Zhang ET; Carvajal C; Gardell L; Quirion R; Dumont Y; Lai J; Porreca F
J Neurosci; 2002 Nov; 22(22):9858-67. PubMed ID: 12427842
[TBL] [Abstract][Full Text] [Related]
22. Neuropeptide Y is Up-regulated and Induces Antinociception in Cancer-induced Bone Pain.
Diaz-delCastillo M; Christiansen SH; Appel CK; Falk S; Woldbye DPD; Heegaard AM
Neuroscience; 2018 Aug; 384():111-119. PubMed ID: 29852245
[TBL] [Abstract][Full Text] [Related]
23. Effects of an acetone extract of Boswellia carterii Birdw. (Burseraceae) gum resin on rats with persistent inflammation.
Fan AY; Lao L; Zhang RX; Wang LB; Lee DY; Ma ZZ; Zhang WY; Berman B
J Altern Complement Med; 2005 Apr; 11(2):323-31. PubMed ID: 15865500
[TBL] [Abstract][Full Text] [Related]
24. The ability of neuropeptide Y to mediate responses in the murine cutaneous microvasculature: an analysis of the contribution of Y1 and Y2 receptors.
Chu DQ; Cox HM; Costa SK; Herzog H; Brain SD
Br J Pharmacol; 2003 Sep; 140(2):422-30. PubMed ID: 12970079
[TBL] [Abstract][Full Text] [Related]
25. Enhanced descending modulation of nociception in rats with persistent hindpaw inflammation.
Ren K; Dubner R
J Neurophysiol; 1996 Nov; 76(5):3025-37. PubMed ID: 8930252
[TBL] [Abstract][Full Text] [Related]
26. Neuropeptide Y tonically inhibits an NMDAR➔AC1➔TRPA1/TRPV1 mechanism of the affective dimension of chronic neuropathic pain.
Fu W; Wessel CR; Taylor BK
Neuropeptides; 2020 Apr; 80():102024. PubMed ID: 32145934
[TBL] [Abstract][Full Text] [Related]
27. Involvement of peripheral neuropeptide Y receptors in sympathetic modulation of acute cutaneous flare induced by intradermal capsaicin.
Lin Q; Zou X; Ren Y; Wang J; Fang L; Willis WD
Neuroscience; 2004; 123(2):337-47. PubMed ID: 14698742
[TBL] [Abstract][Full Text] [Related]
28. Antihyperalgesic effect of systemic dexmedetomidine and gabapentin in a rat model of monoarthritis.
Zhang WS; Xu H; Xu B; Sun S; Deng XM; Zhang YQ
Brain Res; 2009 Apr; 1264():57-66. PubMed ID: 19368840
[TBL] [Abstract][Full Text] [Related]
29. Depressor effect of intrathecal neuropeptide Y (NPY) Is mediated by Y2 subtype of NPY receptors.
Chen X; Westfall TC
J Cardiovasc Pharmacol; 1993 May; 21(5):720-4. PubMed ID: 7685440
[TBL] [Abstract][Full Text] [Related]
30. A potential anti-allodynic mechanism of GDNF following L5 spinal nerve ligation; Mitigation of NPY up-regulation in the touch sense pathway.
Fukuoka T; Noguchi K
Neuroscience; 2015 Sep; 304():240-9. PubMed ID: 26215916
[TBL] [Abstract][Full Text] [Related]
31. Up-regulation and trafficking of delta opioid receptor in a model of chronic inflammation: implications for pain control.
Cahill CM; Morinville A; Hoffert C; O'Donnell D; Beaudet A
Pain; 2003 Jan; 101(1-2):199-208. PubMed ID: 12507715
[TBL] [Abstract][Full Text] [Related]
32. The effect of intrathecal selective agonists of Y1 and Y2 neuropeptide Y receptors on the flexor reflex in normal and axotomized rats.
Xu IS; Hao JX; Xu XJ; Hökfelt T; Wiesenfeld-Hallin Z
Brain Res; 1999 Jul; 833(2):251-7. PubMed ID: 10375701
[TBL] [Abstract][Full Text] [Related]
33. Neuropeptide Y acts at Y1 receptors in the rostral ventral medulla to inhibit neuropathic pain.
Taylor BK; Abhyankar SS; Vo NT; Kriedt CL; Churi SB; Urban JH
Pain; 2007 Sep; 131(1-2):83-95. PubMed ID: 17276005
[TBL] [Abstract][Full Text] [Related]
34. Evidence that the inhibition of luteinizing hormone secretion exerted by central administration of neuropeptide Y (NPY) in the rat is predominantly mediated by the NPY-Y5 receptor subtype.
Raposinho PD; Broqua P; Pierroz DD; Hayward A; Dumont Y; Quirion R; Junien JL; Aubert ML
Endocrinology; 1999 Sep; 140(9):4046-55. PubMed ID: 10465275
[TBL] [Abstract][Full Text] [Related]
35. Central NPY receptor-mediated alteration of heart rate dynamics in mice during expression of fear conditioned to an auditory cue.
Tovote P; Meyer M; Beck-Sickinger AG; von Hörsten S; Ove Ogren S; Spiess J; Stiedl O
Regul Pept; 2004 Aug; 120(1-3):205-14. PubMed ID: 15177939
[TBL] [Abstract][Full Text] [Related]
36. Neuropeptide Y inhibits the trigeminovascular pathway through NPY Y1 receptor: implications for migraine.
Oliveira MM; Akerman S; Tavares I; Goadsby PJ
Pain; 2016 Aug; 157(8):1666-1673. PubMed ID: 27023421
[TBL] [Abstract][Full Text] [Related]
37. Intracerebroventricular injection of a neuropeptide Y-Y1 receptor agonist increases while BIBP3226, a Y1 antagonist, reduces the infarct volume following transient middle cerebral artery occlusion in rats.
Chen SH; Cheung RT
Neuroscience; 2003; 116(1):119-26. PubMed ID: 12535945
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of sympathetic vasoconstriction in pigs in vivo by the neuropeptide Y-Y1 receptor antagonist BIBP 3226.
Lundberg JM; Modin A
Br J Pharmacol; 1995 Dec; 116(7):2971-82. PubMed ID: 8680732
[TBL] [Abstract][Full Text] [Related]
39. Involvement of spinal somatostatin receptor SST(2A) in inflammation-induced thermal hyperalgesia: ultrastructural and behavioral studies in rats.
Zhao J; Hu JY; Zhang YQ; Zhao ZQ
Neurochem Res; 2008 Oct; 33(10):2099-106. PubMed ID: 18452056
[TBL] [Abstract][Full Text] [Related]
40. Evidence that stimulation of two modalities of pituitary luteinizing hormone release in ovarian steroid-primed ovariectomized rats may involve neuropeptide Y Y1 and Y4 receptors.
Jain MR; Pu S; Kalra PS; Kalra SP
Endocrinology; 1999 Nov; 140(11):5171-7. PubMed ID: 10537146
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
